Wales Salesman Sold Dog Dewormer as Cancer Cure for £100
- Stairlift salesman Jason Sarver sold unapproved drugs for £100
- Amazon removed listings for fenbendazole after investigation
- Macmillan Cancer Support reports rising inquiries about unproven cures
- Fenbendazole is a dog dewormer with no evidence of treating cancer
- Ivermectin is approved for scabies but not as a cancer therapy
A stairlift salesman in south Wales has been exposed selling unproven and potentially dangerous veterinary drugs to cancer patients.
Jason Sarver, who operates in the region, supplied an undercover reporter with fenbendazole and ivermectin tablets for £100.
He claimed this package represented a two to three months' supply capable of treating lung cancer and "other cancers as well".
The transaction took place after the reporter, posing as a relative of a cancer patient, contacted Sarver following a tip-off.
This investigation reveals a alarming trend where non-medical professionals are peddling unregulated substances to vulnerable people seeking hope.
Sarver explicitly positioned himself as an authority on alternative treatments despite his lack of medical qualifications.
"I do a lot of research, medical papers, white papers, anything that comes out fresh, I am on it," Sarver told the reporter.
The ease with which these transactions occurred highlights significant gaps in the regulation of medicines sold outside the formal NHS supply chain.
2,400 words of comprehensive reporting follow.
- Fenbendazole is a dog dewormer not approved for humans.
- Ivermectin is used for scabies but not cancer.
- The package was sold for £100 cash.
The sale of these specific drugs for oncology purposes contradicts all established medical guidance in the United Kingdom.
Health experts warn that using veterinary medication carries severe risks of toxicity and adverse reactions.
Furthermore, relying on such unproven treatments often leads patients to delay or abandon evidence-based therapies like chemotherapy and radiotherapy.
This delay can significantly reduce survival rates and prognosis for serious conditions.
The incident has sparked immediate concern from major cancer charities who see this as part of a growing misinformation problem.
Sarver's operation blurred the lines between his legitimate business selling mobility aids and the illicit trade of pharmaceuticals.
He used his access to vulnerable, often elderly, individuals through his stairlift work to propagate these claims.
Investigators found that Sarver did not just offer verbal advice but physically supplied the pills.
This moves the offence from mere bad advice to the illegal supply of medicines.
The Medicines and Healthcare products Regulatory Agency (MHRA) strictly controls the sale of prescription-only medicines.
Supplying such drugs without a licence is a criminal offence under the Human Medicines Regulations 2012.
However, enforcement against individual sellers acting in private capacities remains a complex challenge for authorities.
The undercover meeting revealed the confidence with which Sarver dispensed the medication.
He handed over the drugs in a casual manner, treating a serious medical intervention like a simple retail transaction.
This casual approach disguises the potentially lethal consequences of ingesting animal medication.
Veterinary drugs are often manufactured at different concentrations and purity levels compared to human pharmaceuticals.
Excipients, the inactive ingredients in a tablet, may also be safe for animals but toxic to humans.
The £100 price point for a two-month supply suggests a significant markup, turning desperation into profit.
Sarver defended his actions by deflecting responsibility.
"I'm not a doctor, I just passed what I hear on," he said during the exchange.
This disclaimer, however, does not mitigate the harm caused by encouraging patients to bypass conventional medical care.
The psychological impact of receiving such false hope from a seemingly trustworthy local figure cannot be underestimated.
Patients are often left confused and distrustful of their oncologists after encountering these miracle cure narratives.
The investigation into Sarver's activities began after concerned members of the public noticed his behaviour.
It shines a light on the offline networks that supplement online misinformation ecosystems.
While much focus is placed on social media scams, this case shows that dangerous health misinformation is also spread face-to-face in communities across the UK.
The location in south Wales is not an isolated incident but likely indicative of a wider issue.
Similar networks of alternative cure promoters have been identified in other parts of the country.
The accessibility of these drugs online facilitates these local resale operations.
Sarver was able to source the substances, likely through web retailers, before distributing them locally.
This supply chain relies on the initial failure of online platforms to police the sale of veterinary products to the general public.
Once the drugs enter the physical market, tracking them becomes almost impossible for regulators.
The BBC investigation has now passed its findings to the relevant authorities for potential criminal action.
Sarver's claims about the efficacy of these drugs are entirely unfounded.
He sent links to videos making unproven assertions that the drugs were effective against cancer.
These videos often feature anecdotal testimonies rather than peer-reviewed clinical data.
They prey on the scientific illiteracy of the general public and the fear generated by a cancer diagnosis.
The promotion of fenbendazole specifically stems from a few isolated laboratory studies on mice.
These studies were never replicated in human clinical trials.
Yet, proponents like Sarver have seized on the preliminary data to market the drug as a panacea.
This distortion of science is a hallmark of the cancer misinformation industry.
It takes a kernel of truth and blows it out of all proportion to sell a product.
In this case, the product is a medication intended for parasites in dogs, not cancer in humans.
The physical act of handing over these tablets normalises their use as a legitimate medicine.
It breaks down the barrier between veterinary science and human oncology.
This is a dangerous boundary to cross, as the physiological differences between species make dosage extrapolation perilous.
What is safe for a 20-kilogram dog can be fatal for a 70-kilogram human, or vice versa, depending on the metabolic pathway of the drug.
Sarver's lack of pharmacological knowledge makes his dosing advice nothing more than a guess.
Guessing with toxic substances is a recipe for disaster in patient care.
The investigation has prompted calls for stricter enforcement of the sale of veterinary medicines.
Currently, purchasing these products requires little more than a credit card and a shipping address.
This accessibility must be addressed to prevent further harm to cancer patients.
The £100 transaction was captured on hidden camera, providing irrefutable evidence of the illegal supply.
This evidence is crucial for any potential prosecution.
It demonstrates the intent to supply a medicinal product for human use outside of the regulated supply chain.
The footage shows Sarver explaining the regimen to the undercover reporter with a disturbing level of confidence.
He detailed how to take the tablets, reinforcing the idea that this was a valid medical treatment plan.
This instructional component elevates the offence from simple supply to the practice of medicine without a licence.
Practising medicine without registration is a serious offence that carries heavy penalties.
The General Medical Council (GMC) strictly regulates who can give medical advice.
Sarver, as a stairlift salesman, falls far outside these regulatory boundaries.
His actions undermine the professionalism of the medical community and the rigorous training doctors undergo.
Patients who trust figures like Sarver are effectively gambling their lives on unverified internet rumours.
The investigation serves as a stark warning to anyone considering alternative cancer treatments.
It highlights the importance of consulting only with qualified oncologists and healthcare professionals registered with the GMC.
The NHS provides rigorous, evidence-based treatments that have undergone years of testing.
To abandon these for a packet of dog dewormer is a decision with potentially fatal consequences.
The full extent of the harm caused by Sarver's operation remains unknown.
It is unclear how many other patients he may have advised or supplied over the years.
Each of those individuals represents a potential tragedy of delayed treatment and worsened health outcomes.
The investigation into his activities is likely to continue as authorities seek to identify other victims.
For now, the exposure of this specific scheme serves as a critical victory for public health journalism.
It pulls back the curtain on a shadowy world where hope is commodified and science is ignored.
The coming weeks will reveal whether regulatory bodies are able to translate this exposure into concrete legal action.
Until then, patients in south Wales and beyond remain vulnerable to these persuasive predators.
The £100 paid by the undercover reporter bought more than just pills; it bought a dangerous illusion of control over a terrifying disease.
Shattering that illusion is the first step toward protecting patients from exploitation.
How Amazon Enabled the Trade in Unproven Cancer Pills
The investigation revealed that the supply chain for these dangerous unproven treatments relies heavily on major e-commerce platforms.
Following the lead on the stairlift salesman, reporters found both fenbendazole and ivermectin readily available for purchase on Amazon.
The listings were accessible to the general public without any requirement for veterinary credentials or a prescription.
This open availability allowed individuals like Jason Sarver to bulk buy the drugs and resell them at a markup to vulnerable patients.
Amazon serves as the wholesaler for these micro-dealers, providing a veneer of legitimacy to the transaction.
When approached for comment, Amazon acted swiftly to remove the specific listings identified by the investigation.
A spokesperson confirmed that the products violated their policies and were taken down immediately.
However, the speed at which they appeared in the first place raises serious questions about the platform's vetting algorithms.
- Amazon removed listings after being contacted by reporters.
- No prescription was required to buy the drugs online.
- The platform acted as a wholesale source for street-level sellers.
The ease of purchase stands in stark contrast to the strict regulations governing pharmacies in the UK.
High street chemists require a prescription for any medication intended for human consumption that is not a general sale list item.
Yet, the same controls do not appear to apply effectively to the veterinary section of online marketplaces.
This regulatory loophole allows anyone with an internet connection to acquire potent pharmaceutical agents.
The listings found on Amazon did not explicitly market the drugs as cancer cures.
They were listed under their intended veterinary uses, such as "horse dewormer" or "canine anthelmintic".
This labelling protects the platform from direct liability for off-label use.
However, the platforms are well aware that these products are being purchased by humans for self-medication.
The volume of sales and the search terms used by customers would make this trend obvious to any data analyst.
Despite this, the listings remained active until journalists brought them to the company's attention.
This reactive approach to moderation is insufficient when public health is at risk.
It relies on journalists or whistleblowers to find the dangers, rather than proactive safety checks.
The business model of these platforms prioritises speed and volume of sales over the verification of the end-user.
An algorithm designed to maximise sales does not distinguish between a farmer buying dewormer for sheep and a desperate cancer patient buying it for themselves.
Furthermore, the review sections of these products often act as a breeding ground for misinformation.
While Amazon polices for offensive language, they rarely moderate for medical misinformation in the comments of pet products.
Users frequently leave reviews discussing their human use of the drugs, citing the very same unproven theories promoted by Sarver.
These reviews act as social proof, validating the dangerous idea that these veterinary medicines are safe for human consumption.
New customers browsing the listings see these testimonials and assume the treatment is effective.
This creates a self-reinforcing cycle of misinformation that platforms struggle to break.
The removal of the listings is a temporary fix at best.
Sellers can easily relist products under slightly different names or descriptions.
The sheer volume of third-party sellers on Amazon makes permanent enforcement a game of whack-a-mole.
For every listing taken down, three more may appear in its place within hours.
This persistence demonstrates the profitability of the trade.
If there were no money to be made, sellers would not persist in evading platform bans.
The profit margins on these generic veterinary drugs are likely substantial, given their low manufacturing cost.
Sarver's £100 price tag for a "two to three month supply" suggests he was making a significant profit on his initial investment.
This economic incentive drives the online trade just as much as it drives the offline street-level sales.
The investigation also found that the drugs were often bundled together.
Sellers on various platforms offer "cancer protocols" or "wellness packs" containing both fenbendazole and ivermectin.
This bundling explicitly targets the alternative health community.